A detailed history of Cathie Wood (Ark Investment Management LLC) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Ark Investment Management LLC holds 2,216,365 shares of NRIX stock, worth $44 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
2,216,365
Previous 2,323,332 4.6%
Holding current value
$44 Million
Previous $48.5 Million 2.62%
% of portfolio
0.47%
Previous 0.44%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$18.93 - $25.69 $2.02 Million - $2.75 Million
-106,967 Reduced 4.6%
2,216,365 $49.8 Million
Q2 2024

Jul 26, 2024

SELL
$12.02 - $21.3 $3.75 Million - $6.65 Million
-312,006 Reduced 11.84%
2,323,332 $48.5 Million
Q1 2024

Apr 18, 2024

SELL
$7.77 - $15.66 $4.35 Million - $8.76 Million
-559,661 Reduced 17.52%
2,635,338 $38.7 Million
Q4 2023

Jan 17, 2024

BUY
$4.25 - $10.71 $2.56 Million - $6.45 Million
601,952 Added 23.21%
3,194,999 $33 Million
Q3 2023

Oct 18, 2023

BUY
$7.86 - $10.08 $2.61 Million - $3.35 Million
331,976 Added 14.68%
2,593,047 $20.4 Million
Q2 2023

Jul 10, 2023

BUY
$8.7 - $13.28 $184,544 - $281,695
21,212 Added 0.95%
2,261,071 $22.6 Million
Q1 2023

Apr 17, 2023

BUY
$8.56 - $13.26 $2.15 Million - $3.34 Million
251,605 Added 12.65%
2,239,859 $19.9 Million
Q4 2022

Jan 24, 2023

BUY
$9.86 - $14.59 $6.92 Million - $10.2 Million
701,732 Added 54.54%
1,988,254 $0
Q3 2022

Oct 17, 2022

BUY
$12.33 - $19.81 $6.26 Million - $10.1 Million
507,797 Added 65.21%
1,286,522 $16.8 Million
Q2 2022

Jul 11, 2022

BUY
$7.88 - $14.82 $3.05 Million - $5.73 Million
386,734 Added 98.66%
778,725 $7.86 Million
Q1 2022

Apr 19, 2022

BUY
$12.94 - $29.65 $4.5 Million - $10.3 Million
348,044 Added 791.96%
391,991 $5.49 Million
Q4 2021

Jan 28, 2022

BUY
$26.43 - $34.5 $1.16 Million - $1.52 Million
43,947 New
43,947 $1.27 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track Cathie Wood's Portfolio

Track Cathie Wood Portfolio

Follow Cathie Wood (Ark Investment Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.